Human beta-1,4-Galactosyltransferase 1/B4GalT1 Antibody Summary
Accession # P15291
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
beta -1,4‑Galactosyltransferase 1/B4GalT1 in HeLa Human Cell Line. beta -1,4-Galactosyltransferase 1/B4GalT1 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Mouse Anti-Human beta -1,4-Galactosyltransferase 1/B4GalT1 Monoclonal Antibody (Catalog # MAB36091) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: beta-1,4-Galactosyltransferase 1/B4GalT1
beta 4GalT1 is one of seven beta 1,4 galactosyltransferases that transfer galactose in a beta 1,4 linkage to acceptor sugars including GlcNAc, and Glc, and Xyl. By sequence similarity, the beta 4GalTs form four groups: beta 4GalT1 and beta 4GalT2, beta 4GalT3 and beta 4GalT4, beta 4GalT5 and beta 4GalT6, and beta 4GalT7 (1). beta 4GalT1 is unique among the seven enzymes because it can be expressed either as membrane associated form or secreted form (2). The secreted form is restricted to lactating mammary tissues where the enzyme forms a heterodimer with alpha -lactalbumin to catalyze the synthesis of lactose (3). The membrane form can reside either in the Golgi apparatus, where it adds galactose to N-acetylglucosamine residues, or on cell surface, where it functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix (4). The two enzymatic forms result from alternate transcription initiation sites and post-translational processing (5). Defects in beta 4GalT1 are the cause of congenital disorder of glycosylation type 2D (CDG2D) (6). The amino acid sequence of human B4GALT1 is 88%, 87% and 71% identical to that of rat, mouse/canine and chicken.
- Amado, M. et al. (1999) Biochim. Biophys. Acta. 1473:35.
- Yamaguchi, N and Fukuda, M.N. (1995) J. Biol. Chem. 270:12170.
- Appert, H.E. et al. (1986) Biochem. Biophys. Res. Commun. 138:224.
- Lopez, L.C. et al. (1991) J. Biol. Chem. 266:15984.
- Mengle-Gaw, L. et al. (1991) Biochem. Biophys. Res. Commun. 176:1269.
- Hansske, B. et al. (2002) J. Clin. Invest. 109:725.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human beta-1,4-Galactosyltransferase 1/B4GalT1 Antibody
There are currently no reviews for this product. Be the first to review Human beta-1,4-Galactosyltransferase 1/B4GalT1 Antibody and earn rewards!
Have you used Human beta-1,4-Galactosyltransferase 1/B4GalT1 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image